Meag Munich Ergo Kapitalanlagegesellschaft MBH lessened its stake in shares of UnitedHealth Group Inc (NYSE:UNH) by 55.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,080 shares of the healthcare conglomerate’s stock after selling 128,653 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH’s holdings in UnitedHealth Group were worth $20,080,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Blue Chip Partners Inc. purchased a new position in UnitedHealth Group during the second quarter valued at $110,000. Bruderman Asset Management LLC bought a new stake in UnitedHealth Group during the second quarter valued at about $114,000. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its holdings in UnitedHealth Group by 433.3% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 640 shares of the healthcare conglomerate’s stock valued at $119,000 after acquiring an additional 520 shares during the period. BDO Wealth Advisors LLC bought a new stake in UnitedHealth Group during the second quarter valued at about $121,000. Finally, Acrospire Investment Management LLC increased its holdings in shares of UnitedHealth Group by 130.7% in the second quarter. Acrospire Investment Management LLC now owns 706 shares of the healthcare conglomerate’s stock worth $131,000 after purchasing an additional 400 shares during the last quarter. 86.09% of the stock is owned by institutional investors.
Shares of UnitedHealth Group Inc (NYSE UNH) opened at $232.90 on Wednesday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.70 and a current ratio of 0.70. UnitedHealth Group Inc has a 12 month low of $156.09 and a 12 month high of $235.00. The stock has a market cap of $225,180.00, a PE ratio of 26.47, a PEG ratio of 1.53 and a beta of 0.66.
UnitedHealth Group (NYSE:UNH) last posted its earnings results on Tuesday, January 16th. The healthcare conglomerate reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.50 by $0.09. The business had revenue of $52.06 billion for the quarter, compared to analyst estimates of $51.57 billion. UnitedHealth Group had a net margin of 4.50% and a return on equity of 21.52%. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same period in the prior year, the company posted $2.11 EPS. research analysts predict that UnitedHealth Group Inc will post 9.99 earnings per share for the current year.
In related news, insider Thomas E. Roos sold 975 shares of the stock in a transaction that occurred on Thursday, October 19th. The shares were sold at an average price of $205.47, for a total transaction of $200,333.25. Following the completion of the transaction, the insider now owns 24,630 shares of the company’s stock, valued at approximately $5,060,726.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gail R. Wilensky sold 5,600 shares of the stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $223.31, for a total transaction of $1,250,536.00. Following the transaction, the director now directly owns 61,137 shares of the company’s stock, valued at approximately $13,652,503.47. The disclosure for this sale can be found here. Insiders have sold a total of 34,630 shares of company stock valued at $7,669,416 in the last 90 days. Insiders own 0.89% of the company’s stock.
Several brokerages have recently issued reports on UNH. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $235.00 target price on shares of UnitedHealth Group in a report on Tuesday. Piper Jaffray Companies reissued a “buy” rating and set a $259.00 price objective on shares of UnitedHealth Group in a research note on Wednesday. Wells Fargo & Co restated an “outperform” rating and set a $245.00 target price (up previously from $230.00) on shares of UnitedHealth Group in a research report on Wednesday, November 29th. Leerink Swann restated an “outperform” rating on shares of UnitedHealth Group in a research report on Friday, December 1st. Finally, Citigroup boosted their target price on UnitedHealth Group from $213.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, October 18th. Three investment analysts have rated the stock with a hold rating and twenty-five have given a buy rating to the stock. UnitedHealth Group currently has a consensus rating of “Buy” and an average target price of $230.22.
TRADEMARK VIOLATION WARNING: “UnitedHealth Group Inc (UNH) Stake Lessened by Meag Munich Ergo Kapitalanlagegesellschaft MBH” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/17/unitedhealth-group-inc-unh-shares-sold-by-meag-munich-ergo-kapitalanlagegesellschaft-mbh.html.
UnitedHealth Group Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.